Poseida Therapeutics (PSTX) announced the U.S. FDA has granted Orphan Drug Designation for the treatment of multiple myeloma to P-BCMA-ALLO1, a novel BCMA-targeted allogeneic, T stem cell memory-rich chimeric antigen receptor-T therapy candidate. The company is investigating P-BCMA-ALLO1 in partnership with Roche (RHHBY) for the treatment of relapsed/refractory multiple myeloma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PSTX:
- 3 Best Stocks to Buy Now, 3/11/2024, According to Top Analysts
- Poseida Therapeutics Announces Executive Leadership Change
- Poseida Therapeutics reports Q4 EPS (27c), consensus (39c)
- Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
- PSTX Earnings this Week: How Will it Perform?